Personal information

No personal information available

Biography

William “Wes” Salomon, PhD has been in the field of RNA therapeutics and research for over 15 years. Dr. Salomon was one of the first employees at RXi Pharmaceuticals where he co-discovered their “self-delivering” RNAi platform. He left RXi to earn a doctoral degree in Biochemistry at the University of Massachusetts Medical School studying under Philip Zamore, PhD. His doctoral research focused on the mechanism of Argonaute proteins and the RNAi pathway to which it was published in Cell and named “Paper of the Year” by the Oligonucleotide Therapeutics Society in 2016. Dr. Salomon continued his career in the biotech industry at Intellia Therapeutics as a Principal Scientist evaluating new gene editing technologies and advancing the company’s understanding of the kinetics CRISPR-Cas9 editing when delivered by LNPs. He is currently the Director of Delivery Biology at Tessera Therapeutics where his team translates Gene Writer platform technologies into therapeutically relevant delivery models that will support Tessera’s therapeutic programs.

Activities

Employment (2)

Tessera Therapeutics: Somerville, Massachusetts, US

2019-04 to present | Director (Delivery Biology)
Employment
Source: Self-asserted source
William Salomon

Intellia Therapeutics (United States): Cambridge, Massachusetts, US

2016-01 to 2019-04 | Principal Scientist (Nuclease Biology)
Employment
Source: Self-asserted source
William Salomon

Education and qualifications (2)

University of Massachusetts Chan Medical School: Worcester, Massachusetts, US

2009-09 to 2015-12 | Doctor of Philosophy Biomedical Sciences (Biochemistry and Molecular Pharmacology, RNA Therapeutics Institute)
Education
Source: Self-asserted source
William Salomon

Worcester Polytechnic Institute: Worcester, Massachusetts, US

2001-08 to 2005-05 | Bachelor of Science (Biology and Biotechnology)
Education
Source: Self-asserted source
William Salomon

Professional activities (1)

American Society of Gene Therapy and Cell Therapy: Milwaukee, Wisconsin, US

Member
Membership
Source: Self-asserted source
William Salomon

Works (9)

Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo

Nucleic Acids Research
2018-03-16 | Journal article
Part of ISSN: 0305-1048
Part of ISSN: 1362-4962
Contributors: Matthew R Hassler; Anton A Turanov; Julia F Alterman; Reka A Haraszti; Andrew H Coles; Maire F Osborn; Dimas Echeverria; Mehran Nikan; William E Salomon; Loïc Roux et al.
Source: Self-asserted source
William Salomon

A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing.

Cell reports
2018-02-01 | Journal article
Contributors: Finn JD; Smith AR; Patel MC; Shaw L; Youniss MR; van Heteren J; Dirstine T; Ciullo C; Lescarbeau R; Seitzer J et al.
Source: Self-asserted source
William Salomon

Single-Molecule Imaging Reveals that Argonaute Reshapes the Binding Properties of Its Nucleic Acid Guides.

Cell
2015-07-01 | Journal article
Contributors: Salomon WE; Jolly SM; Moore MJ; Phillip D. Zamore; Serebrov V
Source: Self-asserted source
William Salomon

Rapid and specific purification of Argonaute-small RNA complexes from crude cell lysates.

RNA (New York, N.Y.)
2012-12-18 | Journal article
Contributors: C. Fabián Flores-Jasso; Carlos Fabián Flores-Jasso; Salomon WE; Phillip D. Zamore
Source: Self-asserted source
William Salomon

Argonaute divides its RNA guide into domains with distinct functions and RNA-binding properties.

Cell
2012-11-01 | Journal article
Contributors: Liang Meng Wee; Carlos Fabián Flores-Jasso; C. Fabián Flores-Jasso; Salomon WE; Phillip D. Zamore
Source: Self-asserted source
William Salomon

Argonaute protein identity and pairing geometry determine cooperativity in mammalian RNA silencing.

RNA (New York, N.Y.)
2011-08-30 | Journal article
Contributors: Broderick JA; Salomon WE; Ryder SP; Aronin N; Phillip D. Zamore
Source: Self-asserted source
William Salomon

Glucan particles for selective delivery of siRNA to phagocytic cells in mice.

The Biochemical journal
2011-06-01 | Journal article
Contributors: Tesz GJ; Aouadi M; Prot M; Sarah MC Nicoloro; Boutet E; Amano SU; Goller A; Wang M; Guo CA; Salomon WE et al.
Source: Self-asserted source
William Salomon

Potent and systematic RNAi mediated silencing with single oligonucleotide compounds.

RNA (New York, N.Y.)
2011-04-14 | Journal article
Contributors: Lapierre J; Salomon W; Cardia J; Bulock K; Lam JT; Stanney WJ; Ford G; Smith-Anzures B; Woolf T; Joanne Kamens et al.
Source: Self-asserted source
William Salomon

Modified dsRNAs that are not processed by Dicer maintain potency and are incorporated into the RISC.

Nucleic acids research
2010-02-18 | Journal article
Contributors: Salomon W; Bulock K; Lapierre J; Pavco P; Woolf T; Joanne Kamens
Source: Self-asserted source
William Salomon